RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo3000.2016
T1  - Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas
A1  - D. Nakayama
A1  - H. Nishi
A1  - R. Kato
A1  - Y. Sagawa
A1  - F. Terauchi
A1  - K. Isaka
K1  - Biweekly administration; Docetaxel; Carboplatin; Endometrial carcinoma; Ovarian carcinoma.
YR  - 2016
SP  - 488
AB  - <p><i>Objective: </i>To examine efficacy and safety of biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas. <i>Material and Methods</i>: The recommended doses were determined in the phase I study. In the phase II feasibility study, the primary end-point was safety, and the secondary end-point was response rate and progression-free survival (PFS). <i>Results</i>: The recommended doses of docetaxel and carboplatin were determined to be 45 mg/m<sup>2</sup> and AUC 3.0, respectively, in phase I study. In phase II feasibility study, no treatment-related death was observed. Most non-hematotoxicity cases were mild or moderate. Grade 4 neutropenia was confirmed in 13 patients (31.0%), whereas all cases showed tolerability with 2.6 days delay of anticancer drugs administration in both groups. Response rate was 55.0% in the ovarian carcinoma group, and average PFS was 8.7 months. In the endometrial carcinoma group, response rate was 50.0% and average PFS was 32.0 months. <i>Conclusion</i>: The present results showed that biweekly administration of docetaxel and carboplatin for advanced and recurrent endometrial and ovarian carcinomas results in acceptable side effects, response rate, and PFS.</p>